Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates

PURPOSE: Vercirnon is a CCR9 chemokine receptor antagonist being developed for the treatment of Crohn’s disease. As a variety of concomitant medications are often required for the treatment of Crohn’s disease, it is important to characterise the drug interaction profile of vercirnon. To confirm the...

Descripción completa

Detalles Bibliográficos
Autores principales: Haberer, Lynda J., McSherry, Iain, Cargill, Anna, McCarthy, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889518/
https://www.ncbi.nlm.nih.gov/pubmed/24100471
http://dx.doi.org/10.1007/s00228-013-1592-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889518/
https://www.ncbi.nlm.nih.gov/pubmed/24100471
http://dx.doi.org/10.1007/s00228-013-1592-7

Ejemplares similares